MedTrace Logo

Quality Assurance of Secondary Immunodeficiencies (SID) in CLL/MM Patients

NCT04172467 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1086

Last updated 2022-01-10

Study results available
· View outcomes & findings →

Summary

Retrospective, representative registry for quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)

Conditions

  • Secondary Immunodeficiencies (SID)

Interventions

OTHER

non-interventional retrospective epidemiological observational study

non-interventional retrospective epidemiological observational study

Sponsors & Collaborators

  • Prof. Hartmut Link

    collaborator UNKNOWN

  • Takeda

    collaborator INDUSTRY

  • MMF GmbH

    collaborator INDUSTRY

  • AIO AG Supportivtherapie

    collaborator OTHER

  • AG Supportive Maßnahmen in der Onkologie

    collaborator OTHER

  • AIO-Studien-gGmbH

    lead OTHER

Principal Investigators

  • Hartmut Link, Prof. Dr. · AIO AG Supportive Therapie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-28
Primary Completion
2020-04-25
Completion
2020-08-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04172467 on ClinicalTrials.gov